Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
59.32
-1.76 (-2.88%)
Nov 17, 2026, 4:00 PM EST
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 4.25B CNY in the quarter ending September 30, 2026, with 1,736.09% growth. This brings the company's total for the last twelve months to 4.98B, up 720.14% year-over-year. In the year 2025, Dizal (Jiangsu) Pharmaceutical had annual revenue of 801.14M with 122.60% growth. That makes Dizal (Jiangsu) Pharmaceutical the 9,088th largest company in the world by revenue and 1,431st in China.
Revenue (ttm)
4.98B
Revenue Growth
+720.14%
P/S Ratio
5.54
Revenue / Employee
4.94M
Employees
990
Market Cap
27.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 801.14M | 441.23M | 122.60% |
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Humanwell Healthcare (Group) | 24.49B |
| Beijing Tongrentang | 15.01B |
| Changchun High-Tech Industry (Group) | 10.53B |
| Livzon Pharmaceutical Group | 10.22B |
| Zhejiang Huahai Pharmaceutical | 9.60B |
| Shijiazhuang Yiling Pharmaceutical | 7.93B |
| Dong-E-E-Jiao | 6.87B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.22B |